BNTX - Novavax Stock Forecast: Where Is It Likely Heading By 2025?

• A direct comparison between 4 much discussed COVID vaccines has shown the 2 mRNA-based vaccines from BioNTech/Pfizer and Moderna as superior.
• Novavax’s genetically engineered protein vaccine, while effective, had a less impressive profile.
• Novavax is late to the party and still has big costs to get its vaccine approved for Emergency Use Authorization covering the various age groups.
• COVID has a way to run, but the BioNTech/Pfizer and Moderna mRNA vaccines are proving to be the vaccines of choice.
• It is hard to see Novavax competing with the mRNA vaccines or the mountains of cash BioNTech/Pfizer and Moderna have for new developments.

For further details see: